drugset
drugset / Trial / NCT05966701

The MAD Study of SSGJ-613 in Healthy Subjects

NCT05966701 ↗

Phase 1 Unknown 36 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the safety and tolerability of SSGJ-613 after multiple subcutaneous injections in healthy subjects.

Timeline

Start
2023-08-10
Primary completion
2024-03-10
Completion
2024-03-10

Drugs

EvaluationDrugModalityDoseRoute
Subject SSGJ-613 Monoclonal antibody — Subcutaneous

Indications

gout